Winning also, Tutogen Medical (TTG) was up 75 cents, or 8.6%, to $9.47. Roth Capital upgraded the company from hold to buy Thursday morning.In other analyst action: Friedman Billings changed its price target for Valeant Pharmaceuticals (VRX - Get Report) from $26 to $22. And Merriman Curhan Ford downgraded Coley Pharmaceuticals (COLY), whose developmental program suffered Pfizer's (PFE) axe Wednesday, from buy to neutral. Valeant closed down 4 cents to $16.95, and Coley Pharmaceutical closed up 16 cents, or 4.6%, to $3.62.
Thursday's Health Winners & Losers
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.